Teprenone

DB15955InvestigationalSmall molecule

Teprenone is a medication indicated in the treatment of acute gastroenteritis, exacerbations of gastric inflammation, and gastric ulcers. A medication used to treat ulcers and inflammation of the digestive tract.

Mechanism: Teprenone acts as an anti-ulcer and gastric mucoprotective agent used to treat gastric ulcers and gastritis. Currently, the full mechanisms of action are still unclear.
Curator reviewed
Formula / weight: C₂₃H₃₈O · 330.556 g/mol (avg)
Also known as: Geranylgeranylacetone · Tetraprenylacetone
Code names: E-0671

Resolves to

Compound

UNII57B67OXM8FCAS6809-52-5ChEMBLCHEMBL79686KEGGC13297

Clinical / RWD

RxNorm1362746ATCA02BX15

Structure

InChIKeyHUCXKZBETONXFO-NJFMWZAGSA-NSMILESCC(C)=CCC\C(C)=C\CC\C(C)=C\CC\C(C)=C\CCC(C)=O

Targets

Q00613HSF1

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

2Structured indicationsCondition, population, route and combination as fields, not prose

2Marketed productsAcross 1 country and 2 labellers

1ATC codeIncluding every combination product, plus 6 drug categories

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Teprenone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In